Abiomed (ABMD) Receives FDA IDE Approval for Use of New Impella RP in Pivotal Clinical Study  
11/12/2012 7:44:50 AM

DANVERS, Mass., Nov. 12, 2012 (GLOBE NEWSWIRE) -- Abiomed, Inc. (Nasdaq:ABMD), a leading provider of breakthrough heart support technologies, announced today that it received Investigational Device Exemption (IDE) approval from the Food & Drug Administration (FDA) for the use of the new Impella® RP (Right-side Percutaneous) in a pivotal clinical study in the United States.